Skip to main content
Premium Trial:

Request an Annual Quote

Interleukin s Alticor Alliance Nets a Distribution Deal and $2M Cash

NEW YORK, March 16 (GenomeWeb News) - Building on a year-old partnership with Alticor, the parent company of Amway, Interleukin Genetics today said it has signed a distribution agreement for its genetic tests with another Alticor subsidiary to secure an additional $2 million in capital.

Interleukin signed a distribution agreement for its DNA-based risk assessment tests with Access Business Group International LLC, a subsidiary of Alticor that engages in "development, sourcing, manufacture, and distribution of Amway-branded products," according to the Access Business Group website.

This agreement is considered a "milestone" under a strategic alliance that Interleukin and Alticor initiated last March, under which Interleukin received equity funding of around $16 million in stock, credit, and cash.

According to Interleukin, the criteria for the the milestone required that it enter into a genetic testing agreement "with one or more customers of such size that the projected internal rate of return with respect to the project is at least 20 percent with a payback period of three years or less."

The distribution agreement will net Interleukin an additional $2 million capital contribution from Alticor with no additional shares being issued to Alticor.

Interleukin said it is planning to launch a genetic testing product next year.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more